Emily Winslow Profile
Emily Winslow

@EmilyWinslow4

Followers
1K
Following
6K
Media
46
Statuses
721

Medstar HPB Surgeon, Patient Experience Advocate, DC transplant, Clinical outcomes researcher, TN Vol/WI Badger, and wife/mother of 2. “My opinions are mine 😀”

Washington, DC
Joined October 2015
Don't wanna be here? Send us removal request.
@GBloomfieldMS
Grace Bloomfield, MS
1 year
Had a great time on the hill meeting with lawmakers about health equity, access to cancer screening, @StopTheBleed & more with @SSATNews & @AmCollSurgeons Thankful for @GUMedicine’s proximity to Congress & the opportunity to advocate for our patients
@SSATNews
SSAT
1 year
SSAT Lobby Day in DC! Thank you Anthony Vine for all of your work!
0
1
7
@ajs_stars
AJS Student and Resident Scholar (STARS) Committee
2 years
🌟 #ArticleOfTheWeek 🌟 "Survival disparities in rural versus urban patients with pancreatic neuroendocrine tumor" by Drs. @Muhammadbmirza @PaulaSmithMDPhD, @mary_dillhoff, @FlavioRochaMD, @EmilyWinslow4, @skmaithel. 👀 https://t.co/vnLC0N46l8 📚 @AmJSurgery
0
6
17
@AshleyKiemen
Ashley Kiemen
2 years
Read about how we use CODA to 3D print pancreas microanatomy from serial histological sections, out today in Advanced Materials Technologies. Big thanks to the Johns Hopkins WSE manufacturing team who helped us with the printing 🤗 https://t.co/wZrkN5liX1
4
11
61
@ctisus
Elliot K Fishman / CTisus.com
2 years
Carcinoma Tail of Pancreas
0
5
27
@RuthHe12
Ruth He, MD, PhD
2 years
Heated discussion on liver transplant for ICC, IO therapy in HCC with different etiology, 2nd line HCC design. Fun session👍.
@DAVAOnc
DAVA Oncology
2 years
Continuing our morning with a very interactive discussion featuring our HCC panel. So many good questions! #DAVABermudaGI @docamitgs @Amitmahipal79 @RuthHe12 @nicole_rich8 @pgholam @MaenAbdelrahim
0
2
5
@juampirocca
Juan Pablo Rocca
2 years
Completed another robotic donor right hepatectomy with @BenSamstein. This time we invited @JHawksworthMD to maximize our 🤖LD experience on both campuses. 👉 https://t.co/wL9GLYyVe9 (different case) @WCMSurgery @ColumbiaSurgery @ILLS_LAPLIVER @ASTSChimera
3
3
29
@HalletJulie
Julie Hallet
3 years
🚨First registry-linked collaborative RCT using NSQIP @AHPBA @AmCollSurgeons ⭐️Pip-taz for antibioprophylaxis in whipple👉🏻⬇️ 30-day SSI in RCT ⭐️New standard of care & new way to run multi-centre trials 👏🏻Congrats everyone! @MichaelDAngeli2 https://t.co/EvtO38OWJv
jamanetwork.com
This phase 3 randomized clinical trial examines the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative surgical site infection incidence compared with standard care...
@JAMA_current
JAMA
3 years
Study findings support the use of piperacillin-tazobactam as perioperative antimicrobial prophylaxis for open pancreatoduodenectomy. https://t.co/vI0fBMTas5
1
19
49
@UofTSurgOnc
UofT Surgical Oncology
3 years
More content with our @UofTSurgery team on day 1 of #SSO2023 tomorrow Talk assessment and management of older adults for #HPBSurgery in #SSOHUB with @HalletJulie and panelists @EmilyWinslow4 @aarringtonmd1 & Kamran Idrees 🗓4:45PM in HUB Theater @_CSSO @SocSurgOnc
0
5
21
@TsengJennifer
Jennifer F Tseng MD MPH
3 years
$$$ matter! I challenge you to find any surgical society with higher R0I than @SSATNews. Active annual dues are only $155; trainees $20! Meeting registration for full active members is only $210 with early bird (ENDS TODAY) & $310 after ... https://t.co/YCOPw8MmS6
0
6
27
@michael_lidsky
Michael Lidsky, MD, FACS
3 years
#HAI consortium surgeons at #AHPBA2023 | together with medical oncology colleagues, we are working to advance the field and define the role of HAI for #CRLM and intrahepatic cholangio. Q: How? A: Modern-day RCTs. Coming soon to a pump center near you. @eaonc @colontown @curecc
7
18
96
@Gio_Marchegiani
Giovanni Marchegiani
3 years
Setting the standards 📐 of common bile duct and pancreatic duct 🌱 CBD up to 8 mm < 65 y/o and up to 11 mm in ≥65 y/o 🍡 PD diameters up to 3 mm in <65 y/o and up to 4 mm in ≥65 y/o Landmark open access @Gut_BMJ paper 👏 kudos to authors ! 👉 https://t.co/hGEkfeVeRc
2
86
236
@RuthHe12
Ruth He, MD, PhD
3 years
Nice collaboration with Dr. Jill Smith: repurpose a Cholecystokinin receptor antagonist to modify the tumor microenvironment by increasing CD8 T cells and decreasing fibrosis in HCC.
@RueschCenter
Cure GI Cancers
3 years
This week we highlighted a paper coauthored by Ruesch Center, @gumedcenter, and @LombardiCancer researchers including, Narayan Shivapurkar, @RuthHe12, and Jill P. Smith et al in @IJMS_MDPI. View the full tailored weekly GI Cancer publication output via: https://t.co/17abkAITVD.
0
2
5
@priyanka_kanth
Priyanka Kanth,MD,MS
3 years
Great day attending and presenting at the MedStar Pancreatobiliary diseases conference! @MedStarGUH @MedStarHealth @RueschCenter @EmilyWinslow4 @DrRCJha @ReetuMukherjiMD @DrWalidChalhoub @RuthHe12
2
6
27
@MedicalCollege
Medical College of Wisconsin
3 years
Congratulations to Dr. Douglas B. Evans for receiving the 2022 Luminary Award for GI Cancer, presented by @RueschCenter and @OncLive, which recognizes individuals who have made transformative strides in the lives of patients with GI cancers. Learn more: https://t.co/8J0ILa3unL
5
9
81
@AmyOxentenkoMD
Amy Oxentenko, MD, MACP, MACG, AGAF
3 years
📣 Special pub alert!📣 Why special?🤷🏻‍♀️ 👩🏼‍⚕️Most meaningful piece to write 👩🏻‍⚕️Ability to showcase strides made 👩🏾‍⚕️Platform to note remaining disparities 👩🏿‍⚕️Selected pub date - Feb 3rd!!! Thank you @AmJGastro! #IamBlackwell #NWPD #NationalWomenPhysiciansDay https://t.co/dST9Danruy
3
36
118
@STS_CTsurgery
The Society of Thoracic Surgeons
3 years
Congratulations to cardiothoracic surgeon Thomas E. MacGillivray, MD, from MedStar Health, on being elected 2023-24 President of The Society of Thoracic Surgeons. An STS member since 2003, he has served the Society in various leadership roles. https://t.co/BVYNbXD0lL
1
8
87
@graokane
Grainne O'Kane
3 years
✅ absence of gene alterations (-ve hyperselection) in ctDNA predicts benefit from pani rather than sideness!👇 ❓are we excluding pts from EGFRi with sidedness alone ➡️more to come & validation studies needed A biomarker study of the phase III PARADIGM trial @ASCO #GI23 #CRCSM
2
14
49
@ArndtVogel
Arndt Vogel
3 years
🔥Excellent news: Pivotal phase III IMbrave050 study is positive: The first positive adjuvant trial in #HCC🔥 👉Atezolizumab + Avastin improves RFS in pts at high risk of recurrence following surgery @myESMO @OncoAlert @EASLedu #livertwitter
0
70
165
@HalletJulie
Julie Hallet
3 years
There’s still time to register! Join us tonight to discuss all things HCC & trials with a ⭐️ panel of experts 👇🏻
@SocSurgOnc
Society of Surgical Oncology
3 years
Join @HalletJulie, @AEjaz85, @AdamYopp, @EmilyWinslow4, @graokane and @MarkYarchoan tonight to discuss recent, ongoing, and upcoming trials for hepatocellular carcinoma. Register at https://t.co/MhZ8pLyfVf. #HCC
0
3
5
@pashtoonkasi
Pashtoon Kasi MD, MS
3 years
🙌🏾 🗞️Our #ctDNA🩸🧬paper in the #JITCTop10! MSI⬆️ #PancreasCancer …median PFS/OS NOT REACHED …among the 9 patients treated with ICI, 7/9 were alive at the time of data cut-off 1 who went for surgery➡️pathCR! #JITC #PANCSM @jitcancer Top🔟 @sitcancer @OncoAlert #OpenAccess
@jitcancer
Journal for ImmunoTherapy of Cancer
3 years
Countdown to 2023: #JITCTop10 - Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer https://t.co/ieDgJ6XaCD @pashtoonkasi @doctorC369
4
30
111